MX2021006648A - Uso de vectores lentivirales que expresan el factor ix. - Google Patents
Uso de vectores lentivirales que expresan el factor ix.Info
- Publication number
- MX2021006648A MX2021006648A MX2021006648A MX2021006648A MX2021006648A MX 2021006648 A MX2021006648 A MX 2021006648A MX 2021006648 A MX2021006648 A MX 2021006648A MX 2021006648 A MX2021006648 A MX 2021006648A MX 2021006648 A MX2021006648 A MX 2021006648A
- Authority
- MX
- Mexico
- Prior art keywords
- lentiviral
- lentiviral vectors
- fix
- targeted
- hemophilia
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/644—Coagulation factor IXa (3.4.21.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
- C12N2740/16052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente descripción proporciona vectores lentivirales que comprenden una secuencia de ácido nucleico que codifica un polipéptido con actividad de factor IX (FIX), y métodos para usar dichos vectores lentivirales. Los vectores lentivirales dirigidos al hígado descritos en la presente memoria pueden usarse para terapia génica, en donde la administración génica lentiviral permite la integración estable del casete de expresión del transgén en el genoma de las células diana (p. ej., hepatocitos) de sujetos pediátricos (p. ej., neonatales) o adultos, consiguiendo una mejoría en la expresión de FIX a dosis bajas del vector lentiviral. La presente descripción también proporciona métodos para tratar trastornos hemorrágicos tales como la hemofilia (p. ej., hemofilia B) que comprenden administrar a un sujeto que lo necesita un vector lentiviral dirigido al hígado que comprende una secuencia de ácido nucleico que codifica un polipéptido con actividad de secuencia de FIX a dosificaciones bajas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862776393P | 2018-12-06 | 2018-12-06 | |
PCT/US2019/064711 WO2020118069A2 (en) | 2018-12-06 | 2019-12-05 | Use of lentiviral vectors expressing factor ix |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021006648A true MX2021006648A (es) | 2021-07-07 |
Family
ID=69024682
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021006648A MX2021006648A (es) | 2018-12-06 | 2019-12-05 | Uso de vectores lentivirales que expresan el factor ix. |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200199626A1 (es) |
EP (1) | EP3891289A2 (es) |
JP (1) | JP2022514465A (es) |
KR (1) | KR20210100661A (es) |
CN (1) | CN113396223A (es) |
AU (1) | AU2019393880A1 (es) |
BR (1) | BR112021010047A2 (es) |
CA (1) | CA3121786A1 (es) |
CO (1) | CO2021008877A2 (es) |
IL (1) | IL283547A (es) |
MX (1) | MX2021006648A (es) |
SG (1) | SG11202105880TA (es) |
TW (1) | TW202039855A (es) |
WO (1) | WO2020118069A2 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2959747T3 (es) | 2013-02-15 | 2024-02-28 | Bioverativ Therapeutics Inc | Gen del factor VIII optimizado |
LT3411478T (lt) | 2016-02-01 | 2022-09-26 | Bioverativ Therapeutics Inc. | Optimizuoti viii faktoriaus genai |
WO2023198930A1 (en) * | 2022-04-14 | 2023-10-19 | Genespire S.R.L. | Lentiviral vector |
GB202205615D0 (en) * | 2022-04-14 | 2022-06-01 | Genespire S R L | Lentiviral vector |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0461200B1 (en) | 1989-02-21 | 1997-01-22 | Washington University | Modified forms of reproductive hormones |
US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
DE69703974T2 (de) | 1996-10-17 | 2001-07-19 | Oxford Biomedica Ltd | Retrovirale vektoren |
GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
US6207455B1 (en) | 1997-05-01 | 2001-03-27 | Lung-Ji Chang | Lentiviral vectors |
US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
AU2001259063A1 (en) | 2000-04-12 | 2001-10-30 | Human Genome Sciences, Inc. | Albumin fusion proteins |
EP1395293B1 (en) | 2001-05-14 | 2009-07-22 | Gbp Ip, Llc | Lentiviral vectors encoding clotting factors for gene therapy |
US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
EP1463751B1 (en) | 2001-12-21 | 2013-05-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
CN100343393C (zh) | 2002-03-15 | 2007-10-17 | 布赖汉姆妇女医院 | 适合治疗剂全身性递送的中央气道给药 |
US6615782B1 (en) | 2002-04-12 | 2003-09-09 | Delphi Technologies, Inc. | Two-step finger follower rocker arm |
ES2298745T3 (es) | 2003-04-24 | 2008-05-16 | Fondazione Centro San Raffaele Del Monte Tabor | Promotores bidireccionales de sintesis y utilizacion de los mismos. |
WO2006007539A1 (en) * | 2004-07-01 | 2006-01-19 | Virxsys Corporation | Vector packaging cell line |
KR20130114758A (ko) | 2005-05-27 | 2013-10-17 | 오스페달레 산 라파엘 에스.알.엘. | Mi-rna를 포함하는 유전자 벡터 |
JP2009504157A (ja) | 2005-08-12 | 2009-02-05 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | アルブミン融合タンパク質 |
US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
GB0614780D0 (en) | 2006-07-25 | 2006-09-06 | Ucb Sa | Biological products |
WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
US20080260738A1 (en) | 2007-04-18 | 2008-10-23 | Moore Margaret D | Single chain fc, methods of making and methods of treatment |
BRPI0811857A2 (pt) | 2007-05-14 | 2014-10-21 | Biogen Idec Inc | Regiões fc (scfc) de cadeia simples, polipeptídeos de aglutinação que as compreendem e métodos relacionados. |
SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
WO2010055413A1 (en) | 2008-11-12 | 2010-05-20 | Fondazione Centro San Raffaele Del Monte Tabor | Gene vector for inducing transgene-specific immune tolerance |
US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
US9050269B2 (en) | 2009-03-10 | 2015-06-09 | The Trustees Of The University Of Pennsylvania | Protection of virus particles from phagocytosis by expression of CD47 |
BRPI1010873B1 (pt) | 2009-04-30 | 2020-04-14 | Fond Centro San Raffaele Del Monte Tabor | usos de um vetor de genes, de uma composição farmacêutica e de uma célula |
ES2705249T3 (es) | 2009-06-08 | 2019-03-22 | Amunix Operating Inc | Polipéptidos reguladores de glucosa y métodos para su producción y uso |
MX354555B (es) | 2009-06-08 | 2018-03-09 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion y su uso. |
AU2010290077C1 (en) | 2009-08-24 | 2015-12-03 | Bioverativ Therapeutics Inc. | Coagulation factor IX compositions and methods of making and using same |
WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
ES2880038T3 (es) | 2009-12-06 | 2021-11-23 | Bioverativ Therapeutics Inc | Polipéptidos quiméricos e híbridos de factor VIII-Fc, y métodos de uso de los mismos |
MX2013000301A (es) | 2010-07-09 | 2013-05-09 | Biogen Idec Hemophilia Inc | Factores quimericos de coagulacion. |
WO2012006623A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Systems for factor viii processing and methods thereof |
CN110054699A (zh) | 2012-07-11 | 2019-07-26 | 比奥贝拉蒂治疗公司 | 具有xten和血管性血友病因子蛋白的因子viii复合物、及其用途 |
WO2015023891A2 (en) | 2013-08-14 | 2015-02-19 | Biogen Idec Ma Inc. | Factor viii-xten fusions and uses thereof |
EP3160478A4 (en) * | 2014-06-30 | 2018-05-16 | Bioverativ Therapeutics Inc. | Optimized factor ix gene |
EA201890423A1 (ru) | 2015-08-03 | 2018-07-31 | Биовератив Терапьютикс Инк. | Слитые белки фактора ix, способы их получения и применения |
-
2019
- 2019-12-05 CN CN201980090827.7A patent/CN113396223A/zh active Pending
- 2019-12-05 AU AU2019393880A patent/AU2019393880A1/en active Pending
- 2019-12-05 CA CA3121786A patent/CA3121786A1/en active Pending
- 2019-12-05 KR KR1020217020427A patent/KR20210100661A/ko unknown
- 2019-12-05 BR BR112021010047-4A patent/BR112021010047A2/pt unknown
- 2019-12-05 JP JP2021531954A patent/JP2022514465A/ja active Pending
- 2019-12-05 TW TW108144569A patent/TW202039855A/zh unknown
- 2019-12-05 EP EP19828456.4A patent/EP3891289A2/en active Pending
- 2019-12-05 US US16/704,400 patent/US20200199626A1/en active Pending
- 2019-12-05 SG SG11202105880TA patent/SG11202105880TA/en unknown
- 2019-12-05 MX MX2021006648A patent/MX2021006648A/es unknown
- 2019-12-05 WO PCT/US2019/064711 patent/WO2020118069A2/en active Application Filing
-
2021
- 2021-05-30 IL IL283547A patent/IL283547A/en unknown
- 2021-07-05 CO CONC2021/0008877A patent/CO2021008877A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
CA3121786A1 (en) | 2020-06-11 |
WO2020118069A2 (en) | 2020-06-11 |
TW202039855A (zh) | 2020-11-01 |
WO2020118069A3 (en) | 2020-07-16 |
SG11202105880TA (en) | 2021-07-29 |
CO2021008877A2 (es) | 2021-07-30 |
BR112021010047A2 (pt) | 2021-08-24 |
EP3891289A2 (en) | 2021-10-13 |
IL283547A (en) | 2021-07-29 |
KR20210100661A (ko) | 2021-08-17 |
JP2022514465A (ja) | 2022-02-14 |
CN113396223A (zh) | 2021-09-14 |
AU2019393880A1 (en) | 2021-07-15 |
US20200199626A1 (en) | 2020-06-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021006648A (es) | Uso de vectores lentivirales que expresan el factor ix. | |
MX2020008152A (es) | Uso de vectores lentivirales que expresan el factor viii. | |
Grisch-Chan et al. | State-of-the-art 2019 on gene therapy for phenylketonuria | |
JP2016500519A5 (es) | ||
MX2021001599A (es) | Moleculas de acido nucleico y sus usos para la terapia genica no viral. | |
MX2021008874A (es) | Adn de extremo cerrado (ceadn) y uso en metodos de reduccion de la respuesta inmunitaria relacionada con tratamiento genico o de acido nucleico. | |
MX2020010994A (es) | Terapia de gen para enfermedades causadas por combinaciones desequilibradas de nucleótidos que incluyen síndromes de agotamiento de adn mitocondrial. | |
Vigna et al. | Efficient Tet-dependent expression of human factor IX in vivo by a new self-regulating lentiviral vector | |
MX2023007609A (es) | Métodos para mejorar la terapia génica no viral. | |
Mendell et al. | 480. Gene therapy for spinal muscular atrophy type 1 shows potential to improve survival and motor functional outcomes | |
Maeder et al. | 687. Therapeutic correction of an LCA-causing splice defect in the CEP290 gene by CRISPR/Cas-mediated genome editing | |
JP2018533970A5 (es) | ||
Wagemaker | Lentiviral hematopoietic stem cell gene therapy in inherited metabolic disorders | |
Locatelli et al. | Autologous gene therapy for hemoglobinopathies: from bench to patient’s bedside | |
Yonemitsu et al. | Immunostimulatory virotherapy using recombinant Sendai virus as a new cancer therapeutic regimen | |
BR112022014103A2 (pt) | Terapia gênica baseada em vírus adeno-associado para fenilcetonúria | |
WO2021154414A3 (en) | Gene therapy for hemophilia b with a chimeric aav capsid vector encoding modified factor ix polypeptides | |
JP2020506714A5 (es) | ||
Asmarin et al. | A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study) | |
CO2022006772A2 (es) | Composiciones y métodos para el tratamiento de los trastornos de almacenamiento de glucógeno | |
JP2022510856A (ja) | Vsvキメラベクター | |
Wang et al. | Protective effect of N-acetylcysteine on the intestinal barrier dysfunction after radiation injury in rats | |
Schiroli et al. | 481. Targeted genome editing in Mouse hematopoietic stem/progenitor cells (HSPC) to model gene correction of SCID-X1 | |
Carter et al. | Gene therapy in tyrosinemia: potential and pitfalls | |
Laoharawee et al. | 484. In Vivo Zinc-Finger Nuclease Mediated Iduronate-2-Sulfatase (IDS) Target Gene Insertion and Correction of Metabolic Disease in a Mouse Model of Mucopolysaccharidosis Type II (MPS II) |